21 May 2013
Keywords: tekturna, helps, speedel, narrow, 3rd-qtr, loss, swiss
Article | 26 November 2007
Swiss biotechnology firm Speedel narrowed its third-quarter 2007 net loss on the back of royalty payments from its hypertension drug
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
26 November 2007
20 May 2013
© 2013 thepharmaletter.com